share_log

TCR2 Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner UBS Oncology Impact Fund L.P.

SEC announcement ·  Jun 5, 2023 16:37
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more